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a  b  s  t  r  a  c  t
A study  was  designed  to  compare  the  efﬁcacy  of NexGard® and  BravectoTM, 2 recently
introduced  oral  ectoparasiticides  containing  isoxazolines,  against  ﬂeas  (Ctenocephalides
felis)  on  dogs.  Twenty-four  healthy  dogs,  weighing  9.2  kg to  28.6  kg,  were  included  in this
parallel  group  design,  randomized,  and  controlled  efﬁcacy  study.  On  Day  −1, the  24 dogs
were  allocated  to 3 study  groups:  untreated  control;  Nexgard® treated  and  BravectoTM
treated.  The  treatments  were  administered  on Days  0, 28  and  56  for  Nexgard® (labelled  for
monthly  administration),  and  once  on  Day 0 for BravectoTM (labelled  for  a  12  week  use).  Flea
infestations  were  performed  weekly  with  100  adult  unfed  C.  felis  on  each  dog  from  Days
42 to  84.  Fleas  were  counted  and  re-applied  at 6 and  12  h post-infestation  and removed
and  counted  24 h post-infestation.  The  arithmetic  mean  ﬂea  count  for  the  untreated  group
ranged  from  62.9  to 77.6  at 24  h  post-infestation,  indicating  vigorous  ﬂea  challenges  on
all  assessment  days.  Both  the Nexgard® and  BravectoTM treated  groups  had  statistically
signiﬁcantly  (p < 0.05)  less  ﬂeas  compared  to  the untreated  group on all  assessment  time
points  and  days.  Signiﬁcantly  fewer  ﬂeas  were  recorded  for NexGard® treated  dogs  com-
pared  to  BravectoTM treated  dogs  at 6 h post-infestation  on  Day  56, 63, 70,  77 and 84 and
at  12  h  post-infestation  on Days  70 and  84. No  statistically  signiﬁcant  (p < 0.05)  differences
were  recorded  between  the treated  groups  at 24 h  post-infestation.  Efﬁcacies  recorded  6 h
post-infestation  for Nexgard® ranged  from  62.8%  (Day  49)  to 97.3%  (Day 56),  and  efﬁca-
cies  ranged  from  94.1%  (Day  49) to 100%  (Days  42, 56,  70 and  84)  at 12  h  post-infestation.
Efﬁcacies  recorded  for  BravectoTM ranged  from  45.1%  (Day  84)  to 97.8%  (Day 42)  at  6  h
post-infestation,  and  from  64.7%  (Day  84) to  100%  (Days  42  and  56)  at 12 h post-infestation.
Efﬁcacies  observed  at 24 h were  100%  for both  products  during the  study  except  99.6% on
Day  84 for  BravectoTM.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
BY-NC. IntroductionFleas represent one of the most prevalent parasites in
omestic carnivores (Beugnet et al., 2014a,b). In addition
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to causing discomfort to pets and their owners, C. felis is
primarily responsible for ﬂea bite allergy dermatitis in both
dogs and cats (Dryden and Rust, 1984). Cat ﬂeas are also
vectors of several pathogens including Dipylidium caninum,
Rickettsia felis, and Bartonella henselae (Otranto et al., 2009a,
2009b).
Although the use of insecticides such as ﬁpronil, imid-
acloprid, selamectin, and spinosad have revolutionized
ss article under the CC BY-NC-SA license (http://creativecommons.org/
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ﬂea control in the recent years, treatment and preven-
tion of cat ﬂea infestations remain a major concern for
pet owners and veterinarians (Beugnet and Franc, 2012;
Halos et al., 2014). Licensed products must reach stan-
dards of efﬁcacy determined by pharmaceutical regulatory
authorities worldwide (e.g. European Medicine Agency
(EMA) in Europe, Environmental Protection Agency (EPA)
or Food and Drug Agency (FDA) in the USA) (EMEA, 2000;
Marchiondo et al., 2013). To meet EMA  guidelines, the efﬁ-
cacy of a drug against ﬂeas must reach at least 95%, 48 h
post infestation for a given time-point in several controlled
standard studies.
Several criteria are judged important for both veterinar-
ians and pet owners: the ease of treatment, the duration of
efﬁcacy, and the speed of kill (Beugnet and Franc, 2012;
Halos et al., 2014; Otranto and Wall, 2008). The con-
venience of administration is a key factor for treatment
compliance. In that aspect, topical spot-on formulations
represented a major advance in the 1990s. More recently,
chewable oral ﬂea or ﬂea and tick control formulations have
been developed. Depending on the palatability, the dogs
may spontaneously consume the chewable tablet which
contains the insecticide-acaricide. Both afoxolaner and ﬂu-
ralaner are new insecticide-acaricide molecules from the
isoxazoline family that act on the insect -aminobutyric
acid receptor (GABA) and glutamate receptors, inhibiting
GABA and glutamate-regulated uptake of chloride ions
resulting in excess neuronal stimulation and death of the
arthropod (Gassel et al., 2014; Lahm et al., 2013; Shoop
et al., 2014). Afoxolaner is the active ingredient of Nexgard®
(Otranto, 2014), and ﬂuralaner is the active ingredient of
BravectoTM (Rohdich et al., 2014). The two formulations
are highly palatable to enhance compliance of treatments
administered by dog owners. Due to their pharmacokinetic
properties and the minimum dose administered, 2.5 mg/kg
of afoxolaner and 25 mg/kg of ﬂuralaner, respectively, they
provide long-lasting insecticidal and acaricidal activity
against ﬂeas and ticks (Letendre et al., 2014; Kilp et al.,
2014). Nexgard® administered to dogs has been shown to
kill 100% of ﬂeas within 24 h after infestation for 5 weeks
(Hunter et al., 2014), and BravectoTM has been demon-
strated to kill 100% of ﬂeas within 48 h after infestation
for 12 weeks, according to the U.S. product label (Bravecto
prescribing information. Summit, NJ, Merck Animal Health,
2014).
Speed of kill is also an important criterion for assessing
a ﬂea control product, because the more quickly ﬂeas are
killed the less likely a pet owner is to observe them on
the pet. Speed of kill also inﬂuences ﬂea egg production,
and faster speed of kill therefore results in less ﬂea egg
Table 1
Study design.
Acclimatation Flea infestations Ranking and
allocation to the 3
groups
Tre
Days −14 to −1 Days −7, 42, 49, 56,
63, 70, 77 and 84
Day −2 (±1 day) Ne
28
2)
Bra
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contamination of the environment (Beugnet et al., 2014a,b;
Hunter et al., 2014; Williams et al., 2014). Both NexGard®
and BravectoTM have demonstrated a ﬂea efﬁcacy above
the threshold of 95% starting as early as 4–8 h after ﬂea
challenges (Beugnet et al., 2014a,b; Hunter et al., 2014).
Based on the published data on the duration of efﬁcacy,
as well as the potential speed of kill, the aim of this study
was  to compare the speed of kill against ﬂeas between
one BravectoTM administration and 3 successive 28 day
administrations of NexGard®, according to their respective
labelling in Europe (Beugnet et al., 2014a,b; Hunter et al.,
2014; Rohdich et al., 2014).
2. Materials and methods
2.1. Study design
The study was  a parallel group design, randomized,
single centre, blinded, controlled, efﬁcacy study. In order
to prevent any bias, the treatments were not adminis-
tered to dogs by an individual involved in performing the
post-administration assessments and observations. The
groups were coded to blind the staff performing post-
administration observations and assessments. The study
was  conducted on three groups of 8 dogs each. The study
was  authorized by both Merial and ClinVet ethical com-
mittees, and was  conducted in respect of the Good Clinical
Practices as described in International Cooperation on Har-
monisation of Technical Requirements for Registration
of Veterinary Medicinal Products (VICH) guideline GL9
(EMEA, 2000). Group 1 dogs remained untreated while
group 2 dogs were treated orally with NexGard® and group
3 dogs with BravectoTM.
The design of the study is shown in Table 1. The study
followed a randomized block design. The 24 dogs included
were ranked within sex in descending order of individual
pre-administration ﬂea counts and subsequently blocked
into eight replicates of three dogs each. Within blocks, dogs
were randomly allocated to three coded groups. The coded
groups were randomly assigned to the treatments by a non-
blinded person external from the study staff.
2.2. Animals
In order to assess the individual susceptibility to ﬂea
bites, 27 dogs were originally challenged with ﬂeas and
the 3 dogs with the lowest ﬂea infestations were excluded.
The 24 included dogs were males and females of mixed
breeds, older than 6 months, with no restriction hair
length, and weighing between 9.2 and 28.6 kg. They were
atments Assessments at 6
and 12 h – in situ
ﬂea counts
Assessments at
24 h – ﬂea counts
and removal
xGard®: Day 0,
 and 56 (Group
vectoTM: Day 0
roup 3)
Days 42,49, 56, 63,
70, 77 and 84
Days −5, 43, 50, 57,
64, 71, 78 and 85
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linically healthy as conﬁrmed by a veterinarian on Day
14, not pregnant, and they had not been treated with a
ong acting topical or systemic acaricide/insecticide during
he 12 weeks preceding Day 0 (day of administration).
The dogs were individually housed in boxes which
onsisted of a 1.69 m × 0.7 m enclosed sleeping area, with
eating provided as necessary, and an outside run of
.69 m × 3.0 m.  A roof covers the kennels and the dogs were
ot exposed to rain. Dogs were provided with chew toys on
 weekly basis.
The animals were fed according to the food manufac-
urer’s recommendation.
.3. Treatment
Treatments were administered in accordance with the
uropean registration labels of NexGard® and BravectoTM
n Days 0, and again on Days 28 and 56 with NexGard®
Table 2). On Day 56, the ﬂea infestation was performed
fter the administration of NexGard®. The dogs were fed
mmediately after administration according to BravectoTM
abelling. All the animals were observed daily (from Days
14 to 85) for general health conditions and clinical signs
f any adverse effects to the treatment.
.4. Flea infestations and counts
A laboratory bred strain (derived from a European iso-
ate) of C. felis was used for all infestations. The ﬂeas were
nfed and of mixed sex. Each dog was infested with 100
eas (sex ratio 50:50) on the days as indicated in Table 1.
Flea counts were conducted by combing at speciﬁed
imes after infestation: 6 h (±30 min), 12 h (±1 h) or 24 h
±2 h) post-infestation.
A ﬁne-toothed ﬂea comb was used to recover ﬂeas
resent in the animal’s fur. The method of combing was  by
everal strokes of the comb in each area of the animal, each
ime moving in the same direction, following the pattern
f the hair coat. Movement, from one part of the animal’s
ur to the next, was via strokes overlapping each other, so
hat no area of fur was missed. The examined areas were:
utside hind legs, including feet; tail and anal areas; lat-
ral area, not including shoulders; abdominal area, from
hest to inside hind legs; fore legs and shoulders, including
eet; all neck and head areas; and dorsal strip from shoul-
er blades to base of tail. After completion of the combing
rocedure for all body areas, the whole procedure was
epeated once more so that all areas were combed at least
wice. During the 6 h and 12 h post-infestation counts, the
ive ﬂeas were placed back on the dog and they were only
nally removed during the 24 h post-infestation counts.
able 2
exGard® and BravectoTM posology.
Group Sample size Product Active in
2 8 NEXGARD Afoxolan
3  8 BRAVECTO FluralaneFig. 1. Comparative efﬁcacy observed during the study at 6 h counts post-
infestation.
2.5. Statistical analysis
Efﬁcacy against ﬂeas was calculated for the treated
groups at each assessment day, in accordance to WAAVP
guidelines, using the Abbott’s formula (Marchiondo et al.,
2013).
Efﬁcacy (%) = 100 × Mc − Mt
Mc
,
where
Mc = arithmetic mean of live ﬂeas on the negative
control group (group 1)
Mt = arithmetic mean of live ﬂeas on the Treatment
− administration groups (groups 2 or 3)
The statistical unit is the speciﬁc group if central values
of a group are compared. In other cases, the statistical unit
is the individual animal.
The groups were compared at each time point by a
one-way ANOVA with an administration effect on the
untransformed live ﬂea counts. SAS Version 9.3 was used
for all the statistical analyses.
3. Results
No adverse events related to any of the treatments were
observed.
Arithmetic ﬂea counts and efﬁcacies based on the vari-
ous time points and days for all groups are summarized in
Table 3 and Fig. 1. The arithmetic mean ﬂea count for the
gredients Dose administered
er 3 g chew (68 mg afoxolaner) for dogs >10–25 kg
6 g chew (136 mg afoxolaner) for dogs
>25–50 kg
r 250 mg chewable for dogs > 4.5–10 kg
500 mg chewable for dogs > 10–20 kg
1000 mg chewable for dogs > 20–40 kg
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Table 3
Efﬁcacy of NexGard® and BravectoTM against ﬂeas during the 12 week period of the study, based on Arithmetic means.
Day & time of ﬂea count Mean (Eff%) Mean (Eff%) p-valuea
Group Untreated NexGard® treated BravectoTM treated
Day 42
6 h 72.8 4.0 (94.5%) 1.6 (97.8%) NS
12  h 70.9 0.0 (100.0%) 0.0 (100.0%) NS
24  h 66.5 0.0 (100.0%) 0.0 (100.0%) NS
Day  49
6 h 90.6 33.8 (62.8%) 20.4 (77.5%) NS
12  h 82.4 4.9 (94.1%) 1.8 (97.9%) NS
24  h 77.6 0.0 (100.0%) 0.0 (100.0%) NS
Day  56
6 h 77.4 2.1 (97.3%) 15.9 (79.5%) 0.0384
12  h 76.8 0.0 (100.0%) 0.0 (100.0%) NS
24  h 74.6 0.0 (100.0%) 0.0 (100.0%) NS
Day  63
6 h 85.4 2.9 (96.6%) 32.8 (61.6%) 0.002
12  h 75.1 0.3 (99.7%) 3.5 (95.3%) NS
24  h 68.3 0.0 (100.0%) 0.0 (100.0%) NS
Day  70
6 h 85.1 11.6 (86.3%) 43.9 (48.5%) 0.0059
12  h 76.0 0.0 (100.0%) 8.9 (88.3%) 0.0486
24  h 62.9 0.0 (100.0%) 0.0 (100.0%) NS
Day  77
6 h 89.9 9.9 (89.0%) 39.1 (56.5%) 0.007
12  h 77.8 0.1 (99.8%) 11.6 (85.0%) NS (0.055)
24  h 69.0 0.0 (100.0%) 0.0 (100.0%) NS
Day  84
6 h 84.8 16.3 (80.8%) 46.5 (45.1%) 0.0065
12  h 73.3 0.0 (100.0%) 25.9 (64.7%) 0.0025
24  h 65.6 0.0 (100.0%) 0.3 (99.6%) NS
een ﬂea
 live ﬂeNS: not signiﬁcant (p-value > 0.05). Bold lines: signiﬁcant difference betw
a One-way ANOVA with an administration effect on the untransformed
negative untreated group ranged from 62.9 to 77.6 at 24 h,
indicating robust ﬂea challenges on all assessment days.
Both the afoxolaner and ﬂuralaner treated dogs had sta-
tistically signiﬁcantly (p < 0.05) less ﬂeas compared to the
untreated control dogs at all assessment time points on all
days of evaluation.
Statistically signiﬁcantly (p < 0.05) fewer ﬂeas were
recorded for the Nexgard® treated dogs compared to the
BravectoTM treated dogs at 6 h post-infestation on Day 56,
63, 70, 77 and 84 and at 12 h post-infestation on Days 70
and 84.
No statistically signiﬁcant (p < 0.05) differences were
recorded between the ﬂea counts recorded for the treated
groups at 24 h post-infestation.
Efﬁcacies recorded at 6 h post-infestation for NexGard®
ranged from 62.8% (Day 49) to 97.3% (Day 56), and at 12 h
post-infestation ranged from 94.1% (Day 49) to 100% (Days
42, 56, 70 and 84).
Efﬁcacies recorded at 6 h post-infestation for
BravectoTM ranged from 45.1% (Day 84) to 97.8% (Day 42),
and at 12 h post-infestation ranged from 64.7% (Day 84) to
100% (Days 42 and 56).
4. Discussion
Insecticidal and acaricidal isoxazolines represent a new
class of ectoparasiticides acting systemically after oral
administration (Shoop et al., 2014; Gassel et al., 2014).
Based on their pharmacokinetic properties, a long-lasting
effect is observed. It is directly linked to the dose of active counts in the two  treated groups.
a counts comparing the two  treated groups.
administered, the peak plasma levels achieved after inges-
tion, the binding on plasmatic proteins, and the drug’s
terminal plasma half-life of 12–15 days for ﬂuralaner for-
mulation and 15.5 (±7.8) days for afoxolaner formulation
(Kilp et al., 2014; Letendre et al., 2014). We  hypothesize
that the speed of kill of ﬂeas should be correlated to the
number of ﬂea bites and amount of blood ingested by
ﬂeas. BravectoTM, dosed at 25 mg/kg minimum, showed
100% efﬁcacy against ﬂeas counted at 48 h after infes-
tation 12 weeks after treatment (BravectoTM prescribing
information. Summit, NJ, Merck Animal Health, 2014).
NexGard®, dosed at 2.5 mg/kg minimum, provided 100%
efﬁcacy against ﬂeas 24 h after infestations at all time-
points in this study, which is comparable to previously
published results (Hunter et al., 2014).
Assessments 24 h after infestation can provide an indi-
cation of killing ﬂeas before most will lay eggs, therefore
impacting the potential for re-infestation (Dryden, 1989).
Assessments at 48 h after infestation are typically used
for regulatory purposes (Marchiondo et al., 2013). Earlier
assessments provide an indication of how fast ﬂeas will be
eliminated, therefore reducing the risk of bites.
A decrease in the speed of kill over time is typi-
cally observed with systemic ﬂea control products during
the time when plasma concentrations of active ingredi-
ent decline due to metabolism and elimination. This was
observed in this study, with signiﬁcant differences in ﬂea
counts between the 2 treated groups at 6 h post-challenges
from Day 56 to Day 84. During this time frame, ﬂuralaner
plasma levels were the result of dosing on Day 0 and were
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eclining according to its terminal half-life (Letendre et al.,
014; Kilp et al., 2014). The decrease in the speed of kill was
ecently studied by Taenzler et al. who demonstrated that
fter ﬂea re-infestations in weeks 4, 8 and 12, the efﬁcacy
f ﬂuralaner at 4 h was 96.8, 91.4, and 33.5%, respectively
Taenzler et al., 2014).
Afoxolaner plasma levels were the result of dosing on
tudy Day 56. Dosing NexGard® every 28 days provided
igniﬁcantly greater efﬁcacy at 6 h – post-infestation than
ne dose of BravectoTM during its last 4 week dosing period.
In this study, the ﬁrst ﬂea counts were initiated at Day
2 as it was assumed by the authors that the efﬁcacy would
tay high for at least for 6 weeks in relation to a high plasma
evel of ﬂuralaner (Gassel et al., 2014). This was somehow
onﬁrmed by the efﬁcacies observed on Day 42 at 6 h which
as 97.8% for BravectoTM. The ﬁrst point where a difference
as signiﬁcant occurred at 6 h counts on Day 56.
A reduction in the prophylactic speed of kill in the last
eeks (weeks 9 to 12) may  have clinical consequences as
oth dog owners and veterinarians may  see ﬂeas on the
reated dogs until they die. The number of ﬂea bites may
lso be more important if ﬂeas take of a longer time to die.
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